Page 5 - Mankind Pharma

Mankind Pharma PAT up 66% in Q1 to Rs 494 crore on revenue growth

Juneja also highlighted a 43 per cent YoY increase in Ebitda as a positive outcome of the company's previous initiatives to improve profitability

Stocks to Watch today, July 5: LTIMindtree, Bandhan Bk, Lupin, Adani Power

Stocks to Watch on Wednesday, July 5: LTIMindtree will replace HDFC in the benchmark Nifty50 index, while LIC Housing Finance will likely replace it in the Nifty Financial Services index

Mankind Pharma's success boosts hopes of more consumer IPOs in India

The company, which raised Rs 4,330 crore ($528 million) in India's second-largest new share sale this year, has seen its shares jump 57% in almost two months, drawing a rush of buy calls from analysts

Up almost 32% since listing, Mankind Pharma draws rush of 'buys'

The company's stock has surged more than 60 per cent since listing, driving its market value to about $8.5 billion

Street signs: Mkts turn skittish near new highs, Index fund inflows & more

The benchmark indices registered declines in the previous two trading sessions, which could be a bearish sign, observe analysts

Pharmacists have finger on pulse of small towns as demand increases

The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) is another major reason for the growth in demand for medicines in smaller towns

Mankind Pharma scales new high; rallies 11% in 3 days post Q4 earnings beat

Currently, the stock was quoting 40 per cent higher over its issue price of Rs 1,080.

Stocks to watch: Coal India, Mankind Pharma, EID Parry, India Pesticides

Stocks to watch on June 1, 2023: From Coal India to Mankind Pharma, here are top stocks to watch in Thursday's trading session

Mankind Pharma's profit after tax up 52% at Rs 294 cr in March quarter

Mankind Pharma on Wednesday reported 52 per cent increase in consolidated profit after tax (PAT) at Rs 294 crore for March quarter 2022-23, aided by robust sales. The company had logged a PAT of Rs 193 crore in January-March 2021-22. Revenue from operations rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period, Mankind Pharma said in a statement. In 2022-23, the PAT declined 10 per cent to Rs 1,310 crore from Rs 1,453 crore in the previous year. "The company maintained its strong growth trajectory during the year..our consumer healthcare business has maintained its double-digit growth with dominant brand leadership in its categories," Mankind Pharma Vice Chairman and Managing Director Rajeev Juneja said. Earlier this month, the Income Tax Department conducted raids on the premises of the company over allegations of tax evasion.

Sensex extends rally to 4th day, ends 123 pts higher; ITC, IT stocks shine

CLOSING BELL ON MAY 30, 2023: The NSE Nifty 50 gained 35 points at 18,634; while the Bank Nifty hit a fresh all-time high at 44,499.

More IPOs need to deliver listing pop to revive retail interest: Analysts

Analysts say retail investors' enthusiasm fizzled out post the muted listing of a majority of public offers in CY22

Mankind Pharma shares bounce back 6% as co clarifies on I-T raid

From a low of Rs 1,356 apiece, the stock vaulted 6 per cent to hit an intra-day high of Rs 1,439

Stocks to Watch on May 12: Adani Total, RIL, TaMo, ONGC, Vedanta, Mankind

Stocks to watch today: Mankind Pharma has confirmed that the Income Tax Department conducted a search at some of the premises/ plants related to the Company and some of its subsidiaries

Income Tax officials search Mankind Pharma's New Delhi office: Report

India's Income Tax Department is conducting searches at Mankind Pharma Ltd's office in New Delhi, a government source told Reuters on Thursday, days after the condom maker's successful public listing

Mankind Pharma jumps 32% on stock market debut due to strong demand

The stellar listing day performance comes even as retail investors gave the Rs 4,326-crore IPO - the largest in more than a year-a miss

Mankind Pharma Ltd surges 23% in Mumbai debut after a $529 mn IPO

Mankind's deal marks the return of mid-to-large-sized debuts in India

Sensex, Nifty end flat after choppy day; Indiabulls RE sinks 20%, Zomato 6%

CLOSING BELL: Among sectors, the Nifty PSU Bank index fell nearly 3 per cent, followed by the Nifty Realty index (close to 1 per cent)

Mankind Pharma lists at 20% premium; should you buy, sell, or hold?

Shares of Mankind listed at Rs 1,300, a 20 per cent premium over its issue price of Rs 1,080 on the National Stock Exchange (NSE) and the BSE

Kansai Nerolac, Canara Bank, Mankind Pharma among top stocks to watch today

Stock to Watch on Tuesday, May 9: Canara Bank's net profit rose 90.6 per cent year-on-year (YoY) at Rs 3,175 crore in Q4FY23

Mankind Pharma to make market debut on Tuesday following a successful IPO

The IPO had seen strong demand from institutional investors even as the retail quota had remained undersubscribed